Corcept Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Corcept Therapeutics Incorporated

29/07/2026 23:40

Corcept Therapeutics Inc CORT.OQ reported quarterly adjusted earnings of 36 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 29 cents.  The mean expectation of five analysts for the quarter was for earnings of one cent per share. Wall Street expected results to range from -9 cents to 6 cents per share.
Revenue rose 31.7% to $256.15 million from a year ago; analysts expected $221.82 million. 
Corcept Therapeutics Inc's reported EPS for the quarter was 36 cents​.
The company reported quarterly net income of $42.14 million.
Corcept Therapeutics Inc shares had risen by 8.3% this quarter and gained 170.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 95.1% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Corcept Therapeutics Inc is $91.50, about 1.6% below its last closing price of $92.95
This summary was machine generated from LSEG data July 29 at 10:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.01
0.36
Beat
Mar. 31 2026 
-0.10
-0.30
Missed
Dec. 31 2025 
0.30
0.20
Missed
Sep. 30 2025 
0.14
0.16
Beat